Andrew Pink

4.3k total citations · 2 hit papers
89 papers, 2.0k citations indexed

About

Andrew Pink is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Andrew Pink has authored 89 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Dermatology, 34 papers in Immunology and Allergy and 26 papers in Physiology. Recurrent topics in Andrew Pink's work include Dermatology and Skin Diseases (67 papers), Allergic Rhinitis and Sensitization (29 papers) and Asthma and respiratory diseases (26 papers). Andrew Pink is often cited by papers focused on Dermatology and Skin Diseases (67 papers), Allergic Rhinitis and Sensitization (29 papers) and Asthma and respiratory diseases (26 papers). Andrew Pink collaborates with scholars based in United Kingdom, United States and Germany. Andrew Pink's co-authors include Juliet N. Barker, Catherine Smith, Richard C. Trembath, Michael A. Simpson, Jonathan I. Silverberg, Francesca Capon, Stephan Weidinger, Thomas Bieber, A. David Burden and Paola Di Meglio and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Journal of Allergy and Clinical Immunology.

In The Last Decade

Andrew Pink

75 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

2021 287 citations Thomas Bieber, Eric L. Simpson et al. profile →
Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

2020 213 citations Jonathan I. Silverberg, D. Toth et al. British Journal of Dermatology profile →

Peers

Countries citing papers authored by Andrew Pink

Since Specialization

Citations

This map shows the geographic impact of Andrew Pink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Pink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Pink more than expected).

Fields of papers citing papers by Andrew Pink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Pink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Pink. The network helps show where Andrew Pink may publish in the future.

Co-authorship network of co-authors of Andrew Pink

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Pink. A scholar is included among the top collaborators of Andrew Pink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Pink. Andrew Pink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE 2025 ·Dermatology and Therapy ·Jonathan I. Silverberg, Eric L. Simpson, Andrew Pink, Stephan Weidinger, Gary Chan, (unknown), Claire Clibborn, (unknown)	1
2	Development of a PsA-like presentation under anti-IL-13 therapy with tralokinumab for atopic dermatitis 2025 ·Lara D. Veeken ·Katya Meridor, (unknown), (unknown), Jane Freeston, Philip Laws, Gabriele De Marco, (unknown), Tom Macleod, Emma Rowbotham, Timothy Palmer, Andrea Di Matteo, Richard Woolf, (unknown), Andrew Pink, (unknown), Bruce Kirkham, Dennis McGonagle	0
3	Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials 2025 ·British Journal of Dermatology ·Kristian Reich, Richard G. Langley, J.F. Silvestre, D. Staumont‐Sallé, Antonio Costanzo, Andrew Pink, Amy S. Paller, Norito Katoh, Andreas Wollenberg, Richard B. Warren, Andrew Blauvelt, (unknown), (unknown), Le Gjerum, Eric L. Simpson	0
4	Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials 2024 ·SKIN The Journal of Cutaneous Medicine ·Kristian Reich, Richard G. Langley, (unknown), D. Staumont‐Sallé, Antonio Costanzo, Andrew Pink, Amy S. Paller, Norito Katoh, Andreas Wollenberg, Richard B. Warren, (unknown), (unknown), Le Gjerum, Eric L. Simpson	2
5	BI33 A case of disseminated herpes zoster in a patient on abrocitinib 2024 ·British Journal of Dermatology ·(unknown), (unknown), Andrew Pink, (unknown), Elaine Agius	0
6	733 - Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data 2024 ·British Journal of Dermatology ·(unknown), Linda Stein‐Gold, Diamant Thaçi, Andrew Pink, Kim Papp, Franz J. Legat, Vivian Laquer, Soo Yeon Cheong, (unknown), (unknown), Christophe Piketty	0
7	Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2) 2024 ·Dermatology and Therapy ·Eric L. Simpson, Vimal H. Prajapati, Yael A. Leshem, Raj Chovatiya, Marjolein de Bruin‐Weller, Sonja Ständer, Andrew Pink, Brian Calimlim, Wan‐Ju Lee, Henrique D. Teixeira, Barry Ladizinski, (unknown), (unknown), (unknown), (unknown), Ayman Grada, Andrew M. Platt, Jonathan I. Silverberg	3
8	Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials 2023 ·American Journal of Clinical Dermatology ·Eric L. Simpson, Andrew Pink, Andrew Blauvelt, Melinda Gooderham, April W. Armstrong, Margitta Worm, Norito Katoh, Ketty Peris, L. Puig, S. Barbarot, (unknown), Louise Abildgaard Steffensen, (unknown), Andreas Wollenberg	15
9	Characterization of a Musculoskeletal Syndrome of Enthesitis and Arthritis in Patients With Atopic Dermatitis Treated With Dupilumab, an Interleukin‐4/13 Inhibitor 2023 ·Arthritis & Rheumatology ·Catherine Hughes, Joseph P. Nathan, (unknown), Andrew Pink, Richard Woolf, Catherine Smith, Bina Menon, Bruce Kirkham	13
10	Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience 2023 ·Journal of Investigative Dermatology ·Antony Raharja, (unknown), Giulia Rinaldi, Teresa Tsakok, (unknown), (unknown), (unknown), Andrew Pink, Richard Woolf, Juliet N. Barker, Catherine Smith, Satveer K. Mahil	3
11	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study 2022 ·SHILAP Revista de lepidopterología ·Suzie Cro, Victoria Cornelius, Francesca Capon, Juliet N. Barker, A. David Burden, C.E.M. Griffiths, Helen J. Lachmann, Helen McAteer, Prakash A. Patel, Andrew Pink, Nick J. Reynolds, Richard B. Warren, Catherine Smith	1
12	Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis 2022 ·American Journal of Clinical Dermatology ·Jonathan I. Silverberg, David N. Adam, (unknown), Sunil Kalia, Jan Gutermuth, Andreas Pinter, Andrew Pink, Andrea Chiricozzi, S. Barbarot, (unknown), (unknown), Stephan Weidinger	37
13	Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic 2022 ·British Journal of Dermatology ·(unknown), Juliet N. Barker, Francesca Capon, Andrew Pink, Richard Woolf, Catherine Smith, Satveer K. Mahil	9
14	Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo‐controlled, randomized, phase III clinical trial (ECZTRA 7)* 2021 ·British Journal of Dermatology ·Jan Gutermuth, Andrew Pink, Margitta Worm, (unknown), (unknown), Stephan Weidinger	66
15	Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial* breakdown → 2020 ·British Journal of Dermatology ·Jonathan I. Silverberg, D. Toth, Thomas Bieber, Andrew Alexis, Boni E. Elewski, Andrew Pink, DirkJan Hijnen, (unknown), B K Bang, C.K. Olsen, Azra Kurbasic, Stephan Weidinger, (unknown)	213
16	161 EUROSTAD Prospective Observational Study: Baseline Characteristics, Atopic Dermatitis Severity, and Patient-Reported Outcomes 2019 ·Journal of Investigative Dermatology ·Marjolein de Bruin‐Weller, Andrew Pink, Annalisa Patrizi, Ana M. Giménez‐Arnau, Tove Agner, (unknown), Shyamalie Jayawardena, Marius Ardeleanu, Urs Kerkmann, E. Rizova	1
17	Impact of UVA on pruritus during UVA /B phototherapy of inflammatory skin diseases: a randomized double‐blind study 2016 ·Journal of the European Academy of Dermatology and Venereology ·Julia‐Tatjana Maul, (unknown), Florian Anzengruber, Andrew Pink, (unknown), Lars E. French, Günther F.L. Hofbauer, Alexander A. Navarini	14
18	Cutaneous lupus erythematosus 2015 ·British Journal of Hospital Medicine ·Thomas J Tull, Andrew Pink, Emma Benton, David D’Cruz	3
19	Erythema nodosum 2012 ·British Journal of Hospital Medicine ·Andrew Pink, Juliet N. Barker	1
20	Functional characterization of the regulatory mechanisms controlling HLA-C expression in psoriasis 2011 ·British Journal of Dermatology ·Andrew Pink, Michael A. Simpson, Glen Brice, Catherine Smith, Nemesha Desai, Peter Mortimer, Juliet N. Barker, Richard C. Trembath	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact